HK Stock Market Move | CHINA RISUN GP(01907) up nearly 4% Middle East situation disrupts energy landscape, company's chemical industry sector expected to contribute to earnings flexibility.
China Xuyang Group (01907) rose by nearly 4%, as of the time of publication, it rose by 3.95% to 3.16 Hong Kong dollars, with a turnover of 1.14 billion Hong Kong dollars.
CHINA RISUN GP (01907) rose by nearly 4% as of the time of publication, with an increase of 3.95%, closing at 3.16 Hong Kong dollars with a trading volume of 1.14 billion Hong Kong dollars.
On the news front, the continued turmoil in the Middle East is disrupting the global energy and chemical supply chain. Debon Securities believes that looking ahead to 2026, the ongoing Middle East geopolitical crisis will drive a substantial increase in international crude oil prices, and the company's chemical business will also see a simultaneous significant increase in prices (such as methanol and caprolactam, with market prices at the end of March rising by over 60% and 30% respectively compared to the beginning of the year). The company's years of planning may lead to a period of substantial harvest.
Furthermore, on April 2, CHINA RISUN GP announced on its official WeChat public account that its independently developed caprolactam to hexamethylene diamine unit completed catalyst filling on March 30, 2026, laying the foundation for production in April. It is expected to produce approximately 30,000 tons in the full year of 2026.
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


